Logo

Tempus

In Brief This Week: Burning Rock Biotech, Biocartis, NYGC, Eagle Genomics, Theradiag, OpGen, More

News items for the week of Jan. 16, 2023.

Tempus, AstraZeneca Collaborate on Response Biomarker Discovery for Small Cell Lung Cancer

This clinical study, called Sculptor, is the first research to emerge from a strategic collaboration between the companies on oncology therapeutics.

In Brief This Week: OpGen, MDxHealth, Dante Genomics, More

New items for the week of Oct. 24, 2022.

Tempus, Kartos Therapeutics to Develop CDx for Skin Cancer Therapy

The test will run on Tempus' xT platform and will be used to identify patients with TP53 wild-type Merkel cell carcinoma who may be eligible for treatment with the drug. 

Tempus, Children's Oncology Group Expand Genomic Testing Access for Pediatric Cancer Patients

Tempus' xT platform will be used to identify patients likely to match for a trial assessing the efficacy of genetically informed treatments in certain pediatric cancers.

Sep 7, 2022

Larger Liquid Biopsy Panels Loom, But Patient Benefit Still Uncertain
Premium

Jun 17, 2022

Tempus, Intermountain Healthcare Strike Precision Cancer Research Alliance

Jun 9, 2022

Tempus, Lilly Ink Partnership to Offer No-Cost NGS for Advanced NSCLC Patients

May 20, 2022

Tempus Takes on Precision Neuropsychiatry With New Research Dataset
Premium

May 9, 2022

Aadi Bioscience Inks NGS Lab Partnerships to Screen Solid Tumor Patients for Fyarro Trial

May 6, 2022

Tempus to Provide NGS Cancer Tests to US Department of Veterans Affairs

Apr 12, 2022

Tempus, Pyramid Biosciences to ID Patients With NTRK Fusion-Driven Cancers for Clinical Trial

Apr 8, 2022

Tempus Sets Sights on Pathology Market With New Informatics, Research Network
Premium

Feb 8, 2022

Tempus Acquires Highline Sciences

Nov 12, 2021

In Brief This Week: Caris Life Sciences, Psomagen, Tempus, CareDx, HTG Molecular, Epigenomics, More

Sep 9, 2021

Cedars-Sinai, Tempus Partner on Molecular Database Initiative

Aug 17, 2021

Tempus Submits PMA Application for Tumor Profiling Assay to FDA

Jun 3, 2021

Rain Therapeutics, Tempus Partner to Identify Patients with MDM2-Amplified Tumors for Basket Trial

May 21, 2021

New Products Posted to GenomeWeb: Tempus, Canopy Biosciences, Lonza, More

Mar 3, 2021

Tempus, Texas Oncology Subsidiary Form Data-Focused Precision Oncology Partnership

Feb 25, 2021

Kronos Bio Doses First Patient in CDK9 Inhibitor Trial With Tempus Performing Sequencing

Feb 12, 2021

New Products Posted to GenomeWeb: Tempus, Active Motif, Immudex, Zymo Research, More

Jan 27, 2021

Tempus, Bristol Myers Squibb Expand Cancer Biomarker Alliance

Jan 13, 2021

Tempus, A2 Biotherapeutics Partner to Develop CDx for Therapy Targeting Loss of Heterozygosity

Jan 12, 2021

JP Morgan Healthcare Conference 2021, Day 1: Roche, Seer, 10x, Guardant, Hologic, Thermo Fisher

Breaking News
The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.